Adjuvanted RSVPreF3 vaccine
Sponsors
GlaxoSmithKline
Conditions
Cardiovascular DiseaseRespiratory Syncytial Virus Infections
Phase 2
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
Active, not recruitingNCT07092865
Start: 2025-08-06End: 2027-07-16Updated: 2026-07-30
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
Not yet recruitingNCT07712380
Start: 2026-08-31End: 2029-05-04Target: 450Updated: 2026-07-17